Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients

被引:20
作者
Porter, Ashleigh [1 ]
Natsuhara, Mandy [2 ]
Daniels, Gregory A. [2 ]
Patel, Sandip Pravin [2 ]
Sacco, Assuntina Gesualda [2 ]
Bykowski, Julie [2 ]
Banks, Kimberly C. [3 ]
Cohen, Ezra E. W. [2 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, 10833 Le Conte Ave,11-262 Factor Bldg, Los Angeles, CA 90095 USA
[2] Moores Canc Ctr, Div Hematol Oncol, La Jolla, CA USA
[3] Guardant Hlth Inc, Dept Med Affairs, Redwood City, CA USA
关键词
Metastatic; head and neck cancer (HNC); next generation sequencing (NGS); HETEROGENEITY; CETUXIMAB;
D O I
10.21037/tcr.2019.12.70
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Effective targeted therapy is lacking in head and neck cancer ( HNC). The use of next generation sequencing (NGS) has been suggested as a way to potentially expand therapeutic options and improve outcomes. This study was performed in order to further characterize blood sample cell-free circulating tumor DNA (ctDNA) in advanced HNC patients, to determine its ability to identify actionable mutations, and to elucidate its potential role in patient management. Methods: Retrospective analysis of 60 patients with recurrent and metastatic (R/M) HNCs who underwent molecular profiling of blood samples utilizing Guardant360, a 70-gene ctDNA NGS platform. ctDNA sequencing data was compared to tumor NGS data, when available. Best response to therapy was assessed using RECIST measures. Results: The most common tumor type was oropharyngeal squamous cell carcinoma (n=21). Other cancer types included salivary gland (n=8) and thyroid (n=4). The most common mutations identified by blood analysis were TP53 (68% of patients), PIK3CA (34% of patients), NOTCH1 (20% of patients), and ARID1A (15% of patients). These findings were consistent with results from tumor sequencing data (n=30) where TP53 (48%) and PIK3CA (24%) were also the most common. Seventy-three percent (n=22) of patients had alterations identified in blood that were not present in tumor specimens. In patients with squamous cell carcinoma, 66% had an off-label option identified and 90% had a trial option identified, while 50% of patients with salivary primaries had off-label option identified and 75% had trial options identified. All patients (n=3, 100%) with thyroid primaries had off-label and clinical trial options identified. Of patients with actionable mutations, 13% (n=8) received matched targeted therapy (MTT). Three patients had stable disease (37.5%), 3 had progressive disease (37.5%), and 2 (25%) were not evaluated at the time of follow up. Of those who did not receive targeted therapy (n=21), 11 patients had stable disease (52.4%), 9 had progressive disease (42.9%), and 1 had a complete response (4.8%). Conclusions: Alterations identified by ctDNA may help inform management decisions in advanced HNC. The majority of patients had unique mutations identified on ctDNA. The role of NGS of ctDNA should be explored in future studies.
引用
收藏
页码:203 / +
页数:8
相关论文
共 16 条
[11]   Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma [J].
Schwaederle, Maria C. ;
Patel, Sandip P. ;
Husain, Hatim ;
Ikeda, Megumi ;
Lanman, Richard B. ;
Banks, Kimberly C. ;
Talasaz, AmirAli ;
Bazhenova, Lyudmila ;
Kurzrock, Razelle .
CLINICAL CANCER RESEARCH, 2017, 23 (17) :5101-5111
[12]  
Siegel RL, 2017, CA-CANCER J CLIN, V67, P7
[13]   Cetuximab: its unique place in head and neck cancer treatment [J].
Specenier, Pol ;
Vermorken, Jan B. .
BIOLOGICS-TARGETS & THERAPY, 2013, 7 :77-90
[14]   Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer [J].
Villaflor, Victoria ;
Won, Brian ;
Nagy, Rebecca ;
Banks, Kimberly ;
Lanman, Richard B. ;
Talasaz, AmirAli ;
Salgia, Ravi .
ONCOTARGET, 2016, 7 (41) :66880-66891
[15]   Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas [J].
Wang, Yuxuan ;
Springer, Simeon ;
Mulvey, Carolyn L. ;
Silliman, Natalie ;
Schaefer, Joy ;
Sausen, Mark ;
James, Nathan ;
Rettig, Eleni M. ;
Guo, Theresa ;
Pickering, Curtis R. ;
Bishop, Justin A. ;
Chung, Christine H. ;
Califano, Joseph A. ;
Eisele, David W. ;
Fakhry, Carole ;
Gourin, Christine G. ;
Ha, Patrick K. ;
Kang, Hyunseok ;
Kiess, Ana ;
Koch, Wayne M. ;
Myers, Jeffrey N. ;
Quon, Harry ;
Richmon, Jeremy D. ;
Sidransky, David ;
Tufano, Ralph P. ;
Westra, William H. ;
Bettegowda, Chetan ;
Diaz, Luis A., Jr. ;
Papadopoulos, Nickolas ;
Kinzler, Kenneth W. ;
Vogelstein, Bert ;
Agrawal, Nishant .
SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (293)
[16]   The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients [J].
Zill, Oliver A. ;
Banks, Kimberly C. ;
Fairclough, Stephen R. ;
Mortimer, Stefanie A. ;
Vowles, James V. ;
Mokhtari, Reza ;
Gandara, David R. ;
Mack, Philip C. ;
Odegaard, Justin I. ;
Nagy, Rebecca J. ;
Baca, Arthur M. ;
Eltoukhy, Helmy ;
Chudova, Darya I. ;
Lanman, Richard B. ;
Talasaz, AmirAli .
CLINICAL CANCER RESEARCH, 2018, 24 (15) :3528-3538